SC-236

SC-236
[[File:|frameless|220px|alt=|Chemical structure of SC-236]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

SC-236 is a selective cyclooxygenase-2 (COX-2) inhibitor that has been studied for its potential use in treating inflammation and pain. COX-2 inhibitors are a class of drugs that specifically target the COX-2 enzyme, which is responsible for the synthesis of pro-inflammatory prostaglandins.

Mechanism of Action

SC-236 works by selectively inhibiting the COX-2 enzyme, thereby reducing the production of pro-inflammatory prostaglandins. This action helps to alleviate inflammation and pain without affecting the COX-1 enzyme, which is important for maintaining the protective lining of the stomach and regulating blood platelets.

Pharmacokinetics

The pharmacokinetics of SC-236 involve its absorption, distribution, metabolism, and excretion. SC-236 is absorbed into the bloodstream after oral administration and is distributed throughout the body. It is metabolized primarily in the liver and excreted through the kidneys.

Clinical Applications

SC-236 has been investigated for its potential use in treating conditions such as arthritis, cancer, and other inflammatory diseases. Its selective inhibition of COX-2 makes it a promising candidate for reducing inflammation with fewer gastrointestinal side effects compared to non-selective NSAIDs.

Research and Development

Research on SC-236 has focused on its efficacy and safety profile. Studies have shown that SC-236 can effectively reduce inflammation and pain in animal models. However, further clinical trials are necessary to fully understand its potential benefits and risks in humans.

Side Effects

As with other COX-2 inhibitors, potential side effects of SC-236 may include cardiovascular risks, such as an increased risk of heart attack or stroke. Gastrointestinal side effects are generally less common compared to non-selective NSAIDs.

Regulatory Status

As of the latest updates, SC-236 is still under investigation and has not been approved for clinical use by major regulatory agencies such as the FDA or EMA.

Also see

• Cyclooxygenase-2
• Non-steroidal anti-inflammatory drug
• Selective COX-2 inhibitor
• Prostaglandin

This article is a stub related to pharmacology. You can help WikiMD by expanding it!